Stock Market Reviews

Read and share opinions on ESPR (Esperion Therapeutics, Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock mar

Latest News

• Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
  Dec 19, 2025
• Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  Dec 9, 2025
• Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
  Nov 21, 2025
• Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
  Nov 19, 2025
• Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
  Nov 18, 2025
• Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025
  Nov 10, 2025
• ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down
  Nov 7, 2025
• Esperion Therapeutics Inc (ESPR) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ...
  Nov 6, 2025
• Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
  Nov 6, 2025
• Esperion Therapeutics: Q3 Earnings Snapshot
  Nov 6, 2025
• Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
  Nov 4, 2025
• Esperion to Participate in Jefferies Global Healthcare Conference - London
  Nov 3, 2025
• Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.
  Oct 28, 2025
• Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025
  Oct 27, 2025

ESPR News

• Esperion’s Bempedoic Acid Receives Recommendation in 2025 ACC Scientific Statement on Management of Peripheral Artery Disease in Adults With Diabetes
  – Bempedoic Acid Highlighted by ACC for LDL-C Lowering in Patients with Peripheral Artery Disease and Diabetes Based on Proven Cardiovascular and Limb Benefits – ANN ARBOR, Mich., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) welcomed the inclusion of bempedoic acid as a first-line, evidence-based therapy for LDL-C lowering for patients on maximally tolerated statins in the 2025 American College of Cardiology (ACC) Scientific Statement on Management of Peripheral Artery Disease (PAD)
  Dec 19, 2025
• Why The Narrative Around Esperion Therapeutics Is Shifting After Analyst Upgrades And Trial Results
  Esperion Therapeutics has seen its fair value estimate nudged higher to about $6.50 per share from roughly $6.15, even as the discount rate holds steady near 6.96% and revenue growth expectations ease slightly to around 20.4% from approximately 20.7%. This recalibration reflects rising confidence in the company’s long term earnings power, tempered by cautious near term growth assumptions as analysts weigh the pace of commercial execution and market adoption. Read on to see how you can track...
  Dec 10, 2025
• Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  ANN ARBOR, Mich., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on December 4, 2025, the Company granted three new employees (i) non-qualified stock options to purchase an aggregate of 380,000 shares of common stock, all of which were granted to John Harlow, the Company’s newly appointed Chief Commercial Officer, and (ii) 435,536 restricted stock units (RSUs), 424,536 of which were awarded to Mr. Harlow, under Esperion’s 2017 Inducement Equity Incentive Plan. The
  Dec 9, 2025
• Why Analysts Are Rewriting Esperion’s Story After New Pipeline Results and Global Partnerships
  Esperion Therapeutics has recently seen a slight increase in its fair value target, moving from $6.10 to $6.15 per share following adjustments to analysts’ expectations. This modest revision reflects both improved sentiment in recent coverage and evolving outlooks for the company’s potential revenue growth. As the narrative around Esperion continues to shift, staying informed will be key to understanding its future trajectory and opportunities. Analyst Price Targets don't always capture the...
  Nov 25, 2025
• Esperion Partner Otsuka Launches NEXLETOL® in Japan for the Treatment of Hypercholesterolemia
  – Company to Receive $90 Million Total Payment – – Third Largest Global Market for Cardiovascular Prevention Represents Significant Global Growth Opportunity for NEXLETOL – ANN ARBOR, Mich., Nov. 21, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that Otsuka Pharmaceutical Co., Ltd. (Otsuka), the Company’s partner in Japan for the development and commercialization of NEXLETOL® (bempedoic acid) tablets, received National Health Insurance Price Listing and launched NEXLETOL for t
  Nov 21, 2025
• Esperion to Participate in Piper Sandler 37th Annual Healthcare Conference
  ANN ARBOR, Mich., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3, 2025, at 3:30 p.m. ET. The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days. Espe
  Nov 19, 2025
• HLS Therapeutics Announces Health Canada Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
  HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that Health Canada has approved NILEMDO® (bempedoic acid) for use in Canada and has issued a Notice of Non-Compliance ("NON") for NEXLIZET® (bempedoic acid and ezetimibe). HLS in-licensed the exclusive rights to NILEMDO and NEXLIZET for the Canadian market from Esperion Therapeutics Inc. ("Esperion")
  Nov 18, 2025
• Esperion Partner HLS Therapeutics Announces Approval of NILEMDO® for the Reduction of LDL-Cholesterol in Canadians at Risk of Cardiovascular Disease
  ANN ARBOR, Mich., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that HLS Therapeutics Inc. (TSX: HLS), the Company’s partner in Canada for the development and commercialization of NILEMDO® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe), has received approval from Health Canada to market NILEMDO for the reduction of LDL-Cholesterol in Canadians at risk of cardiovascular disease. Commercial launch for NILEMDO is expected in Q2 2026. “This approval marks a
  Nov 18, 2025
• Esperion Announces New Data from CLEAR Outcomes Highlighting Value of NEXLETOL® (bempedoic acid) in Oral and Poster Presentations at the AHA Scientific Sessions 2025
  – Analysis of Patients from CLEAR Outcomes Receiving No Other Background Lipid Lowering Therapies, Bempedoic Acid Alone Reduced MACE-4 by 14% Compared to Placebo – – An Exploratory Analysis of CLEAR Outcomes Reports Patients Who Took Bempedoic Acid Were 42% Less Likely to Experience Venous Thromboembolism Events Compared to Placebo – ANN ARBOR, Mich., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of two post hoc analyses from CLEAR Outcomes focused on
  Nov 10, 2025
• Tracking the Narrative for Esperion Therapeutics as Analyst Optimism Grows Amid Shifting Fundamentals
  Esperion Therapeutics has seen its Fair Value Estimate tick up from $5.80 to $6.10, signaling a modest boost in the company’s assessed intrinsic worth. This adjustment comes as analysts show increasing optimism about the company’s growth prospects and execution in its target markets. Stay tuned to discover key ways you can monitor shifts in the company narrative and stay ahead of future updates. Analyst Price Targets don't always capture the full story. Head over to our Company Report to find...
  Nov 9, 2025
• ESPR's Q3 Earnings Lag Estimates, Revenues Rise Y/Y, Stock Down
  Esperion's Q3 loss widens despite a 69% jump in revenues. Mixed results and investor jitters probably drag ESPR shares down 15%.
  Nov 7, 2025
• Esperion Therapeutics Inc (ESPR) Q3 2025 Earnings Call Highlights: Revenue Surge and Strategic ...
  Esperion Therapeutics Inc (ESPR) reports significant revenue growth and strategic agreements, setting the stage for sustained profitability and market expansion.
  Nov 6, 2025
• Esperion Reports Third Quarter 2025 Financial Results and Provides Business Update
  – Q3 2025 Total Revenue Grew 69% Y/Y to $87.3 Million – – Q3 2025 U.S. Net Product Revenue Grew 31% Y/Y to $40.7 Million – – Reached Settlement Agreement with ANDA Filer, Dr. Reddy’s Laboratories, Not to Market Generic Versions of NEXLETOL® (bempedoic acid) and NEXLIZET® (bempedoic acid and ezetimibe) Prior to April 2040 – – Bempedoic Acid Received Level 1a Recommendation in Updated ESC/EAS Guidelines for Management of Dyslipidemias – – Partner Otsuka Received Regulatory Approval and Favorable P
  Nov 6, 2025
• Esperion Therapeutics (ESPR) Reports Q3 Loss, Tops Revenue Estimates
  Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -77.78% and +4.75%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 6, 2025
• Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  ANN ARBOR, Mich., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on November 4, 2025, the Company granted 23 new employees 77,650 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan. The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement m
  Nov 6, 2025
• Esperion Therapeutics: Q3 Earnings Snapshot
  ANN ARBOR, Mich. AP) — Esperion Therapeutics Inc. ESPR) on Thursday reported a loss of $31.3 million in its third quarter.
  Nov 6, 2025
• Esperion Appoints Industry Veteran John Harlow as Chief Commercial Officer
  – Brings Extensive Executive Leadership Driving Commercial Strategies That Enhance Sales and Marketing Performance – ANN ARBOR, Mich., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the appointment of John Harlow as the Company’s Chief Commercial Officer, effective November 17, 2025. Mr. Harlow will join Esperion’s Executive Leadership Team and will report directly to Sheldon Koenig, President and CEO of Esperion. "We are thrilled to welcome John as our Chief Commercia
  Nov 4, 2025
• Esperion to Participate in Jefferies Global Healthcare Conference - London
  ANN ARBOR, Mich., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that the company will present at the Jefferies Global Healthcare Conference – London on November 18, 2025, at 8:00 a.m. GMT (3:00 a.m. ET). The live webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours after the completion of the call and will be archived on the Company’s website for approximately 90 days.
  Nov 3, 2025
• GS1 Hong Kong Equips Local Businesses to Turn EU's Digital Product Passport Mandate into a Competitive Edge
  GS1 Hong Kong successfully hosted its highly anticipated workshop, "Digital Product Passport: from Compliance to Competitive Edge" on October 27, 2025, equipping local businesses with critical insights and practical strategies to navigate the forthcoming EU Digital Product Passport (DPP) regulations.
  Oct 31, 2025
• Esperion to Host Virtual Investor Key Opinion Leader Event Highlighting Significant Unmet Need in Statin Intolerance on Tuesday, November 11, 2025, at 2:00 p.m. ET.
  – Leading Cardiovascular Physician Experts to Explore Real-World Challenges and Impact on Patient Outcomes – ANN ARBOR, Mich., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event for investors to discuss the clinical and real-world challenges of statin intolerance, its impact on patient outcomes, and the Company’s continued commitment to addressing this significant unmet need. The event will be led by LeAnne Bloedon, VP,
  Oct 28, 2025
• Esperion Announces New Analyses from CLEAR Outcomes to be Presented at the American Heart Association (AHA) Scientific Sessions 2025
  ANN ARBOR, Mich., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that an oral presentation and a poster presentation have been accepted for presentation at the AHA Scientific Sessions 2025 in New Orleans, LA, November 7-10, 2025. Oral Presentation Bempedoic acid monotherapy, LDL cholesterol, and cardiovascular events: a secondary analysis of the CLEAR Outcomes trialNovember 9, 2025, 9:45 – 11:00 AM CSTPresenter: Carolina Pires Zingano, MD (Cleveland Clinic) Poster Pres
  Oct 27, 2025
• Esperion to Report Third Quarter 2025 Financial Results on November 6
  ANN ARBOR, Mich., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will report third quarter 2025 financial results before the market opens on Thursday, November 6, 2025. Following the release, management will host a webcast at 8:00 a.m. ET to discuss these financial results and provide business updates. A live audio webcast can be accessed on the investor and media section of the Esperion website. Access to the webcast replay will be available approximately two hours
  Oct 23, 2025
• CREATING POSITIVE IMPACT IN SUSTAINABILITY
  CREATING POSITIVE IMPACT IN SUSTAINABILITY Sika is advancing its sustainability strategy with the introduction of the Sika® Carbon Compass – an automated platform for calculating Product Carbon Footprints (PCF). The calculation methodology has been independently verified by TÜV Rheinland, Germany, and is in line with internationally recognized standards. With this certified approach, Sika provides reliable, carbon emissions data, allowing its customers to make informed, climate-conscious decisio
  Oct 21, 2025
• ESPR Aims to Diversify With Rare Liver Disease Candidate, Stock Up
  Esperion selects ESP-2001 as a preclinical candidate for primary sclerosing cholangitis, a rare liver disease, aiming to begin clinical studies in 2026.
  Oct 17, 2025
• Esperion Nominates ESP-2001 as Preclinical Development Candidate for Treatment of Primary Sclerosing Cholangitis
  – Highly-Specific Allosteric ACLY Inhibitor Designed to Target Liver and Bile Duct Injury, Inflammation, and Fibrosis Associated with Primary Sclerosing Cholangitis (PSC) and Related Diseases – – ESP-2001 Has the Potential to Meaningfully Impact the Progression of PSC, a Disease with No Approved Treatments – ANN ARBOR, Mich., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the nomination of ESP-2001, the Company’s highly-specific allosteric ATP citrate lyase (ACLY) inhi
  Oct 16, 2025
• Esperion Therapeutics (ESPR): Assessing Valuation After $75 Million Discounted Stock Offering and Share Price Drop
  Esperion Therapeutics (ESPR) just wrapped up a major public offering, raising $75 million by selling common stock at a price below the prior close. This move immediately caused shares to drop, drawing attention from investors. See our latest analysis for Esperion Therapeutics. The public offering hit investor sentiment hard last week, with Esperion's share price tumbling in response to the discounted sale even as the company reached a favorable settlement to block generic competitors. Despite...
  Oct 11, 2025
• ESPR- Japanese Drug Approval, Otsuka Payments to Help this Biotech Play
  Esperion Therapeutics Inc. (ESPR) and its partner Otsuka recently announced regulatory approval for NEXLETOL (bempedoic acid; oral ATP citrate lyase [ACLY] inhibitor) for hypercholesterolemia in Japan. Pending pricing, which ESPR estimates will take roughly one to two months, the company should receive a $120 million milestone from Otsuka, writes John McCamant, editor of Medical Technology Stock Letter.
  Oct 10, 2025
• Why Esperion Therapeutics (ESPR) Is Up After $75M Equity Raise and Generic Settlement News
  Earlier this week, Esperion Therapeutics completed a follow-on public offering of 30,000,000 shares of its common stock at US$2.50 per share, raising total gross proceeds of approximately US$75 million to fund ongoing development and commercialization initiatives. This capital raise occurs alongside a settlement with Dr. Reddy’s Laboratories that prevents generic competition for Esperion’s cholesterol drugs in the U.S. until April 2040, providing more certainty around future revenue streams...
  Oct 10, 2025

ESPR Reviews

• Stonks4Days

  Dec 29, 2025

  $ESPR Feeling the heat, this biotech is about to drop some knowledge!

  Buy

• WallStreetBandit

  Dec 29, 2025

  $ESPR Another overpromised biotech with a questionable future.

  Sell

• BullRunBoss

  Dec 29, 2025

  $ESPR This stock is like a diet soda – sounds healthy, but does it really quench your thirst for returns? 🤔

  Sell

• BuyLowBoi

  Dec 28, 2025

  $ESPR Pullin' some wild claims, but can they keep it up?

  Sell

• CashCombo

  Dec 28, 2025

  $ESPR If this company were a movie, it'd be a rom-com—could go either way, but you’re kinda rooting for it!

  Sell

• StonkRider

  Dec 27, 2025

  $ESPR Focused on advancing cardiovascular therapies, this company has demonstrated resilience in a competitive landscape, backed by strong clinical data that supports its growth potential.

  Buy

• ShortSavage

  Dec 27, 2025

  $ESPR The race against time is on—innovative treatments are either a hit or miss, and this one is hanging by a thread! Watch closely as the market reacts to the next announcement; it could mean everything.

  Sell

• OptionRogue

  Dec 26, 2025

  $ESPR This biopharmaceutical company is committed to addressing unmet medical needs through impactful therapies. Their dedication to research and development has the potential to lead to significant advancements in cardiovascular care.

  Buy

• EquityPulse

  Dec 26, 2025

  $ESPR The pressure is intense as the race against cardiovascular disease continues! Every new development could either save the day or let down countless expectations—stress levels are off the charts!

  Buy

• CapitalRush

  Dec 26, 2025

  $ESPR Focused on transforming cardiovascular care, this company is dedicated to developing innovative solutions. With a strong pipeline and an emphasis on research, it is well-positioned to make a significant impact in the healthcare market.

  Buy

• RiskRaider

  Dec 26, 2025

  $ESPR They’re out of ideas and out of time.

  Sell

• BullRunBandit

  Dec 24, 2025

  $ESPR Hustlin’ hard, but the road's rocky, watch your step.

  Sell

• WallStreetGrim

  Dec 23, 2025

  $ESPR Driven by a commitment to addressing unmet medical needs, this organization has a strong pipeline that could lead to transformative therapies in cardiovascular health. Its recent advancements suggest a promising trajectory.

  Buy

• OptionCipher

  Dec 23, 2025

  $ESPR With their revolutionary approach to cholesterol management, the stakes are sky-high. Will they be hailed as heroes or fall victim to the fierce competition? Tension is palpable!

  Buy

• TendieTitan

  Dec 22, 2025

  $ESPR If this company were a superhero, it would definitely have a cape made of cholesterol-fighting powers. Saving hearts one stock at a time!

  Buy

• GainsOverBrains

  Dec 22, 2025

  $ESPR Pharma's a wild ride, but they need a miracle, no cap.

  Sell

• TheFiscalShade

  Dec 22, 2025

  $ESPR A bit of a wild card, but could surprise the haters!

  Sell

• CandleFreak

  Dec 22, 2025

  $ESPR This biotech firm is focused on addressing significant unmet medical needs with its innovative therapies. Its dedicated research and development efforts highlight a promising future in advancing healthcare solutions.

  Buy

• TradePhantom

  Dec 22, 2025

  $ESPR A therapeutic focus that feels more like a therapy session.

  Sell

• TradeFrenzy

  Dec 22, 2025

  $ESPR Chasing after dreams doesn't cure heart conditions.

  Sell

• PriceBreaker

  Dec 21, 2025

  $ESPR As a player in the pharmaceutical space, this organization is dedicated to addressing cardiovascular health, an area of increasing importance. With a strong focus on innovation and clinical advancements, it may be well-positioned for future growth.

  Buy

• TendieTitan

  Dec 19, 2025

  $ESPR This company is like that kid in class who promises to bring snacks but never does. What’s the deal, Esperion? Where’s the flavor?

  Sell

• PaperHandsGone

  Dec 19, 2025

  $ESPR Strugglin' to find its groove in the biotech scene!

  Sell

• GainMachine

  Dec 18, 2025

  $ESPR If this stock were a diet pill, it would definitely be on the 'too good to be true' list! But hey, who doesn't love some hope?

  Sell

• CapitalCarnage

  Dec 18, 2025

  $ESPR Just what the healthcare sector needed, another disappointment.

  Sell

• TradeReckoner

  Dec 18, 2025

  $ESPR If only their prospects were as good as their marketing.

  Sell

• OptionCipher

  Dec 18, 2025

  $ESPR The race in therapeutics is intense! Breakthroughs are happening, but can they prioritize the right ones and avoid getting left behind? It's a risky game in a high-stakes arena!

  Buy

• TheEarningsBeast

  Dec 18, 2025

  $ESPR This stock is like that DIY life hack you can’t believe actually worked—suddenly, you’re feeling all kinds of smart!

  Buy

• StonkDestroyer

  Dec 17, 2025

  $ESPR More like Esper-tional failure at this point.

  Sell

• MarketWolf

  Dec 17, 2025

  $ESPR Struggling with new data and investor sentiment, this biotech firm is at a crossroads. Will they rise to the occasion or fall flat when it matters most?

  Sell

• TradePulse

  Dec 16, 2025

  $ESPR With breakthroughs on the horizon, this therapeutics firm is on the edge of major innovation, yet the pressure to deliver is immense. Will they make a splash or sink under expectations?

  Sell

• StockShotz

  Dec 16, 2025

  $ESPR This stock is trying to break free from the cholesterol jam. Get ready to boogie with some health-conscious moves!

  Buy

• TradePredator

  Dec 15, 2025

  $ESPR Chasing miracles rarely leads to anything worthwhile.

  Sell

• FiscalFury

  Dec 15, 2025

  $ESPR With enough optimism to fuel a spaceship, this one’s all about chasing that next big health breakthrough!

  Buy

• OptionCipher

  Dec 14, 2025

  $ESPR In the biotech arena, where breakthroughs and failures collide, staying afloat requires nerves of steel – which path will this take?

  Sell

• StockStrider

  Dec 14, 2025

  $ESPR Bullish trend confirmation signal.

  Buy

• BullishBard

  Dec 14, 2025

  $ESPR Looks like a bullish accumulation zone.

  Buy

• FinTechNomad

  Dec 14, 2025

  $ESPR The clock is ticking on FDA approvals, and nerves are frayed. The potential for a major medical breakthrough looms large, but so does the risk of setbacks.

  Sell

• AlgoAce

  Dec 13, 2025

  $ESPR Like a new dance move, this one might take some time to catch on, but it’s got potential!

  Sell

• TradeNova

  Dec 13, 2025

  $ESPR Bears taking control of the chart.

  Sell

• AlphaRogue

  Dec 12, 2025

  $ESPR This company is on a mission to help hearts pump better—bonus points if they can help mine beat a little faster during finals week!

  Buy

• MarketReaper

  Dec 12, 2025

  $ESPR Bulls pushing relentlessly.

  Buy

• CryptoCoyote

  Dec 11, 2025

  $ESPR Risk remains strongly to downside.

  Sell

• AlgoAce

  Dec 11, 2025

  $ESPR If this company were a movie, it would be a heartwarming underdog story, proving that persistence pays off in the end!

  Buy

• CapitalFrame

  Dec 11, 2025

  $ESPR With groundbreaking developments in its therapeutic offerings, this biotechnology firm is addressing critical health challenges and showing promise for future advancements.

  Buy

• TradeHex

  Dec 11, 2025

  $ESPR Sustained buy pressure noted.

  Buy

• TheRiskDealer

  Dec 11, 2025

  $ESPR Charts flashing warning signs.

  Sell

• QuantAssault

  Dec 11, 2025

  $ESPR Market showing strong bearish bias.

  Sell

• DividendFrame

  Dec 11, 2025

  $ESPR Fear dominating the tape.

  Sell

• BearMarketSurvivor

  Dec 11, 2025

  $ESPR Hustling hard in the healthcare game, don’t sleep on this!

  Buy

• QuantKnight

  Dec 11, 2025

  $ESPR Bullish catalysts lining up.

  Buy

• TradeMatrix

  Dec 11, 2025

  $ESPR Downward expansion likely next.

  Sell

• CapitalHex

  Dec 11, 2025

  $ESPR In a rapidly evolving space, this company's focus on addressing unmet medical needs positions it as a forward-thinking leader. Their pipeline and strategic initiatives could yield significant advancements and market opportunities.

  Buy

• TradePhantom

  Dec 10, 2025

  $ESPR Their promises are as empty as their stock price.

  Sell

• RiskAssassin

  Dec 10, 2025

  $ESPR The pressure is mounting as expectations for new treatments rise; it's a do-or-die moment that could either catapult this company to success or plunge it into chaos.

  Sell

• ShortSniper

  Dec 10, 2025

  $ESPR Still waiting for a breakthrough that seems eternally out of reach.

  Sell

• MarginLogic

  Dec 10, 2025

  $ESPR Focusing on lipid management solutions, this company addresses critical health issues with its targeted therapies. Its potential to improve patient outcomes could attract attention from healthcare providers.

  Buy

• CryptoCoyote

  Dec 10, 2025

  $ESPR They're navigating a sea of skepticism with their cholesterol treatments! Will they weather the storm or will skepticism sink them before they reach calmer waters?

  Sell

• BuyLowBro

  Dec 9, 2025

  $ESPR This company's got more ups and downs than a rollercoaster – hang on tight and enjoy the ride!

  Buy

• BearFighter

  Dec 9, 2025

  $ESPR Is innovation a foreign concept here?

  Sell

• ShortCircuit

  Dec 9, 2025

  $ESPR Bearish pressure accelerating quickly.

  Sell

• CryptoCobra

  Dec 8, 2025

  $ESPR This stock feels like trying to explain your favorite meme to your parents – it’s complicated and they just don’t get it!

  Sell

• TheEquityEdge

  Dec 8, 2025

  $ESPR Focusing on cutting-edge therapies, this firm's commitment to addressing unmet medical needs positions it as a pivotal entity in the healthcare sector.

  Buy

• IndexPredator

  Dec 8, 2025

  $ESPR In a market flooded with options, standing out is critical. But can they turn their research into something that captures investors' attention? The clock is ticking!

  Buy

• BuyTheDipBro

  Dec 8, 2025

  $ESPR Chasing those heartbeats, but the market's feeling a little cold.

  Sell

• PortfolioGremlin

  Dec 7, 2025

  $ESPR Working hard in the lab, but the results gotta hit, fam.

  Sell

• VolatilityCore

  Dec 7, 2025

  $ESPR The organization's dedication to pioneering treatments in cardiovascular health signifies its critical role in addressing pressing medical challenges. As the healthcare landscape advances, its innovative pipeline presents promising opportunities for impactful contributions.

  Buy

• TradeRebel

  Dec 6, 2025

  $ESPR Innovation is key, but with fierce competition, the stakes are sky-high! Will they rise to the challenge or get lost in the shuffle?

  Buy

• AlgoAce

  Dec 6, 2025

  $ESPR This company’s research is more intense than a high school chemistry experiment gone wrong. Safety goggles required!

  Buy

• CashClown

  Dec 5, 2025

  $ESPR Movin’ with purpose, tackling health issues like a boss!

  Buy

• BearEater

  Dec 4, 2025

  $ESPR Price expansion coming soon.

  Buy

• BagholderPrime

  Dec 4, 2025

  $ESPR Bearish volatility spike incoming.

  Sell

• TradeRebel

  Dec 4, 2025

  $ESPR Bearish sequence forming on multiple timeframes.

  Sell

• HODLWarrior

  Dec 4, 2025

  $ESPR Price expansion coming soon.

  Buy

• RiskDriver

  Dec 4, 2025

  $ESPR Bearish pattern completing.

  Sell

• CandleCrusher

  Dec 3, 2025

  $ESPR Not a friendly chart for bulls.

  Sell

• TrendStalker

  Dec 3, 2025

  $ESPR A therapeutics firm with more missed targets than actual solutions.

  Sell

• EquityAssault

  Dec 3, 2025

  $ESPR This one's about as useful as a flat tire.

  Sell

• GainVector

  Dec 2, 2025

  $ESPR In the competitive landscape of pharmaceuticals, this company is advancing innovative approaches to cardiovascular health. Continued progress in clinical trials may positively impact its market presence and investor confidence.

  Buy

• AlphaVandal

  Dec 2, 2025

  $ESPR They’re just spinning their wheels with no traction.

  Sell

• DividendJunkie

  Dec 2, 2025

  $ESPR Hoping for a breakthrough? Good luck with that.

  Sell

• TendieTitan

  Dec 1, 2025

  $ESPR Think of this as the cool kid in class—always got the latest trends, but you’re not sure if it’s a phase or the future!

  Sell

• TradeBlaze

  Nov 30, 2025

  $ESPR This company's focus on addressing significant cardiovascular conditions through innovative therapies shows promise in transforming patient outcomes, potentially leading to strong market performance.

  Buy

• CashMeOutside

  Nov 30, 2025

  $ESPR Makin' waves in the health scene, peep that potential, no doubt!

  Buy

• CapitalCrusher

  Nov 30, 2025

  $ESPR This stock is like that awkward moment when someone tries to explain science at a party—interesting but leaves you with more questions!

  Sell

• BearMarketSurvivor

  Nov 29, 2025

  $ESPR Struggling in the game, might be time to rethink the play!

  Sell

• TendieTitan

  Nov 29, 2025

  $ESPR This stock is like that one friend who keeps trying new diets but insists they’re totally fine eating pizza every Friday. Keep an eye on it!

  Sell

• CashOverload

  Nov 29, 2025

  $ESPR Chasing after a miracle cure that might not exist.

  Sell

• CodeTrader

  Nov 29, 2025

  $ESPR The clock is ticking on their breakthroughs, and there’s no room for error. Every announcement sends tremors through the market, making it a nail-biter!

  Buy

• MemeInvestor

  Nov 28, 2025

  $ESPR Owning this stock is like having a secret stash of candy—sweet surprises might just be around the corner!

  Buy

• RiskReaper

  Nov 27, 2025

  $ESPR This innovative company is making strides in the cardiovascular space, focusing on cholesterol management with promising therapies that address significant unmet medical needs. Their commitment to research and development could position them favorably in a competitive market.

  Buy

• BagholderElite

  Nov 26, 2025

  $ESPR They’re hustlin’ hard, might just turn the game around!

  Buy

• CashCombo

  Nov 26, 2025

  $ESPR Trying to cure the world one lipid at a time! Definitely a good chat starter at parties, even if it leaves people confused.

  Sell

• TradeProtocol

  Nov 26, 2025

  $ESPR This stock is like a gym membership—promises a lot but you might end up just sitting on the couch!

  Sell

• MarketGlitch

  Nov 25, 2025

  $ESPR As the race for new therapies intensifies, the pressure is on to prove efficacy. Will this be a breakthrough moment or just another disappointment?

  Sell

• TradeBlitz

  Nov 24, 2025

  $ESPR This stock is like a roller coaster that promises just enough ups to keep your heart racing, but not enough downs to lose lunch!

  Buy

• StonkViking

  Nov 24, 2025

  $ESPR This crew’s tackling tough issues – mad respect for the hustle!

  Buy

• BullishCraze

  Nov 24, 2025

  $ESPR With a commitment to addressing unmet medical needs, this organization is advancing its pipeline with innovative therapies that could significantly impact patients' lives, making them one to watch closely.

  Buy

• MarketNomad

  Nov 24, 2025

  $ESPR This stock is the equivalent of stale bread.

  Sell

• LazyQuant

  Nov 24, 2025

  $ESPR If they were a movie, it’d be a dramatic comeback story with a surprise twist!

  Buy

• CapitalRush

  Nov 24, 2025

  $ESPR With a robust pipeline of innovative therapeutics, this biotech firm is addressing significant unmet medical needs. Its research initiatives are exciting and could lead to breakthroughs in treatment options for patients.

  Buy

• TraderFury

  Nov 23, 2025

  $ESPR The breakthroughs in this field are exciting, but the stakes are incredibly high. How do you cope with the sudden changes that can impact your fortunes? It’s a race against time!

  Sell

• MarginMarauder

  Nov 23, 2025

  $ESPR This company is like a college kid cramming for finals – working hard to get results but still figuring out where they put the snacks!

  Sell

• TrendStalker

  Nov 23, 2025

  $ESPR Still waiting for this one to show some promise.

  Sell

• OptionOverlord

  Nov 23, 2025

  $ESPR This company is like that friend who keeps trying diets—promising big results but still just eating snacks on the couch!

  Sell

• TradeNinja

  Nov 23, 2025

  $ESPR This firm is like a health bar—might not taste great, but it’s packed with potential and keeps you going!

  Buy

• CapitalCreep

  Nov 22, 2025

  $ESPR Chasing lost causes? Typical biotech behavior.

  Sell

• StonkPhantom

  Nov 22, 2025

  $ESPR The clock is ticking on their strategies, and the market is watching closely. Can they execute flawlessly amidst the chaos, or will they be left scrambling in the dust?

  Sell

• MarketMarauder

  Nov 22, 2025

  $ESPR Innovation? More like a lack of direction.

  Sell

• EquityPulse

  Nov 21, 2025

  $ESPR Innovations are crucial, but the pressure to deliver results is intense! Investors are holding their breath, waiting for breakthrough news that could change everything.

  Buy

• GainMachine

  Nov 21, 2025

  $ESPR This one’s like trying to explain a meme to your parents – it has potential, but it might just leave you feeling confused!

  Sell

• BullRaid

  Nov 21, 2025

  $ESPR Another biotech pipe dream that will probably disappoint investors.

  Sell

• CashKiller

  Nov 20, 2025

  $ESPR This one’s just a long wait for nothing.

  Sell

• WallStreetGrim

  Nov 19, 2025

  $ESPR Focusing on critical cardiovascular health, this organization is advancing its pipeline with promising candidates. The potential impact of its innovations on patient outcomes positions it favorably in the healthcare landscape.

  Buy

• TheLongPlay

  Nov 19, 2025

  $ESPR Hit or miss, but got some moves that catch the eye!

  Sell

• BearFighter

  Nov 19, 2025

  $ESPR Health trends can’t save you from mediocrity.

  Sell

• TradePhantom

  Nov 18, 2025

  $ESPR This stock is the poster child for disappointment.

  Sell

• BuyLowBro

  Nov 17, 2025

  $ESPR Think of this as the superhero of the stock world, ready to rescue the day with innovative ideas!

  Buy

• HedgeMeNot

  Nov 16, 2025

  $ESPR Chasing new meds? Gotta watch how that prescription game unfolds.

  Sell

• TradeHex

  Nov 16, 2025

  $ESPR This company is at the forefront of innovative therapies, showcasing substantial potential in addressing significant health needs. With a solid pipeline and recent advancements, it is poised for growth within its sector.

  Buy

• ByteBull

  Nov 16, 2025

  $ESPR This biotech is like a mad scientist in the lab—if they crack the code, we’re all gonna want a taste of that genius!

  Sell

• TheChartCode

  Nov 15, 2025

  $ESPR Trying to figure this one out is like solving a puzzle with missing pieces—frustrating but sometimes rewarding! 🧩😅

  Sell

• GainMachine

  Nov 14, 2025

  $ESPR If health were a band, this company would be the lead singer—always pushing boundaries and making some catchy hits!

  Sell

• RiskReaper

  Nov 13, 2025

  $ESPR Specializing in innovative therapeutics, this organization is committed to addressing significant healthcare needs. Its pipeline of products and ongoing research initiatives showcase a promising future in the pharmaceutical sector.

  Buy

• QuantRift

  Nov 13, 2025

  $ESPR Operating in the biopharmaceutical space, this company is dedicated to addressing high cholesterol and cardiovascular issues with novel therapies. Their strong clinical data and strategic collaborations suggest a bright future.

  Buy

• FinTechFrost

  Nov 13, 2025

  $ESPR Trying to conquer cholesterol like it’s a boss level in a video game—health points are the new currency!

  Buy

• TraderFury

  Nov 13, 2025

  $ESPR With promising innovations on the horizon, this one is generating buzz. But with high expectations come high stakes—can it deliver without crashing?

  Buy

• TheEarningsBeast

  Nov 12, 2025

  $ESPR They’re like the personal trainer who promises to get you in shape – you just hope they don’t make you do burpees!

  Sell

• RiskVandal

  Nov 12, 2025

  $ESPR Chasing hope here is like chasing shadows.

  Sell

• DividendDemon

  Nov 11, 2025

  $ESPR With innovation like this, they’re practically the superhero of heart health! Cape optional, but profits are mandatory.

  Buy

• ProfitVandal

  Nov 11, 2025

  $ESPR A classic case of underwhelming results with overhyped promises.

  Sell

• OptionCipher

  Nov 10, 2025

  $ESPR This company is on a rollercoaster, and you might want to buckle up! With the market's unpredictability, it’s a wild ride you won't want to miss.

  Buy

• Stonks4Days

  Nov 10, 2025

  $ESPR Watch this one, it’s cooking up something good for health!

  Buy

• QuantQuest

  Nov 10, 2025

  $ESPR This stock is like that awkward kid in class who tries hard, but everyone is still kind of confused about the whole deal.

  Sell

• WallStreetHex

  Nov 10, 2025

  $ESPR This company operates in the dynamic field of biotechnology, addressing crucial health challenges with novel therapies. The potential for breakthroughs in treatment options makes them a notable player in the industry.

  Buy

• StonkSamurai

  Nov 9, 2025

  $ESPR This biotech's all about that heart health hustle, watch it pop!

  Buy

• RiskVandal

  Nov 9, 2025

  $ESPR This one is a real head-scratcher, good luck figuring it out.

  Sell

• OptionCipher

  Nov 9, 2025

  $ESPR The stakes are high! This firm is in the spotlight, and the tension is palpable. Exciting times ahead—will it thrive or dive?

  Buy

• ProfitShade

  Nov 8, 2025

  $ESPR Hittin' the health scene with big hopes, watch out for the ride!

  Buy

• RiskVandal

  Nov 7, 2025

  $ESPR nimble loud theta eyes soon oversold tbh fast eyes volume watching soon watching spike mode pumping nimble hands soon momentum trend earnings heating momentum flows patience

  Buy

• BullishBerserker

  Nov 5, 2025

  $ESPR maybe feels king soon-ish heater spicy imo nasty eyes vibes hedges hands levels beastly patience

  Buy

• WallStreetHex

  Nov 1, 2025

  $ESPR pain train express

  Sell

• VolatilityViper

  Oct 29, 2025

  $ESPR buzzing queued humming earnings no tax range earnings maybe check heavy no trigger queued staying range nasty wild mode watching crushing heavy fast theta grind nasty

  Buy

• QuantRift

  Oct 27, 2025

  $ESPR That breakout had better timing than my morning coffee. This chart looks like it just had an energy drink.

  Buy

• YOLOHold

  Oct 25, 2025

  $ESPR Even my coffee is less jittery than this price action. I blinked and lost.

  Buy

• HODLWarrior

  Oct 24, 2025

  $ESPR My portfolio's new hobby: losing gracefully. Chart looks like my.

  Sell

• BagholderPrime

  Oct 21, 2025

  $ESPR gap watching go diamond vibes soon grind today king and bounce gap tight risk

  Buy

• OptionNomad

  Oct 15, 2025

  $ESPR Someone fed the bulls protein shakes again. Chart's climbing like it heard.

  Buy

• YieldSlasher

  Oct 8, 2025

  $ESPR earnings patience loud hard feels noise today soon-ish today on gap hurts talking clear feels oversold imo mode tbh soon-ish it hard vibes

  Buy

• WallStreetVandal

  Oct 7, 2025

  $ESPR Every breakout feels like a high-five from the trading gods.

  Sell

• TradeFrenzy

  Oct 1, 2025

  $ESPR volume investors residence pay cave it's deserve whispering hazard so bear low

  Sell

• StonkSlayer

  Oct 1, 2025

  $ESPR heat vibes vol alpha no staying hands vol no queued volume heating noise heating trigger vol smart wild

  Buy

• DividendVortex

  Oct 1, 2025

  $ESPR Another green candle? Must be a glitch. Volume so low it's whispering sweet nothings.

  Sell

• OptionMatrix

  Sep 29, 2025

  $ESPR a hope not strategy is

  Sell

• RiskReaper

  Sep 26, 2025

  $ESPR soon levels eyes now hedges keeping sentiment city now dead wall clean wild maybe fading soon wild tight whispers hard

  Sell

• BullishMyth

  Sep 20, 2025

  $ESPR a is like regret hope not strategy smells

  Buy

• WallStreetGrim

  Sep 18, 2025

  $ESPR express hazard pain pay deserve train investors

  Sell

• BullBrawler

  Sep 6, 2025

  $ESPR Feels like the market finally woke up on the right side of the.

  Buy

• TradePredator

  Aug 30, 2025

  $ESPR buzzing nasty grind tight imo on on hands money fast hard soon theta whispers tbh today hard soon pumping money on hedges now nimble oversold it

  Buy

• PortfolioFreak

  Aug 26, 2025

  $ESPR queued wild now tape nimble queued heavy today tbh wild trend vibes money fading hedges soon range feels soon-ish hedges wild tax grind today hands rough nimble wild here patience

  Sell

• YieldWarden

  Aug 15, 2025

  $ESPR like therapy stock weak weak stock this hands? bills me more owes

  Sell

• PnLReaper

  May 30, 2025

  $ESPR volume levels spicy diamond it oversold grind range ath move wild mooning volume mooning passed hedges

  Buy

• ShortRaid

  May 11, 2025

  $ESPR tape frankly cliff energy hands whoa smart talking earnings macro talking level-to-level mess maybe clear wall out sauce

  Sell

• TickerFlux

  Apr 2, 2025

  $ESPR sentiment tape alpha pumping momentum macro heavy run check keeping trigger strong

  Buy

• CapitalCarnage

  Feb 26, 2025

  $ESPR ruggy hard hard nimble soon-ish ugly ugly steady nasty heavy

  Sell

• AlgoAce

  Feb 11, 2025

  $ESPR macro tape heater macro queued eyes fire on fire theta range heating king nasty hurts nimble loud vol

  Buy

• CapitalCreep

  Jan 29, 2025

  $ESPR talking diamond macro noise clean hands loud lower candle macro city tight session range ugly soon-ish loud fading

  Sell

• HedgeKnight

  Dec 3, 2024

  $ESPR hard check on and bull no no uptrend vol diamond tax soon

  Buy

• MarginMarauder

  Oct 21, 2024

  $ESPR rip queued earnings choppy humming now my today macro bleeding flows hedges mode humming

  Sell

• CashCraze

  Oct 5, 2024

  $ESPR vibes queued rocket hurts theta steady spicy clean ath oversold rocket gap

  Buy

• CandleFreak

  Sep 21, 2024

  $ESPR passed level-to-level watching trend gains soon whoa king fast soon diamond today range now fire

  Buy

• ShortSavage

  Sep 15, 2024

  $ESPR watching hedges flows no on supply tight levels watching now clear wick soon grind lows theta doom range hedges supply

  Sell

• ChartFang

  Jul 17, 2024

  $ESPR dumping out bear range rough sauce tax trap risk weak macro spike tbh noise grind

  Sell

• CapitalRush

  Mar 6, 2024

  $ESPR eyes bounce clear clean gains smooth whoa keeping spike tax nimble gap smooth no soon-ish tax fire

  Buy

• CandleCrusher

  Mar 2, 2024

  $ESPR printing today patience staying humming on gains tax smart staying and whoa maybe feels clear theta move buzzing king

  Buy

• DividendHunter

  Feb 14, 2024

  $ESPR volume today dripping strong steady heat loud today grind mode check diamond today flows mode money gains hard

  Buy

• DividendGhost

  Jan 24, 2024

  $ESPR grind risk smooth flows check here bounce soon-ish crushing tax breakout level-to-level mode loud money patience check

  Buy

• BullishBerserker

  Nov 16, 2023

  $ESPR bounce hurts spike vibes on hard whoa heavy hands maybe feels oversold mooning watching

  Buy